Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial.

[1]  M. Packer.  Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. , 2018, International journal of cardiology.

[2]  Deepak L. Bhatt,et al.  Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial , 2018, European journal of heart failure.

[3]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[4]  C. Morgan,et al.  Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. , 2016, The American journal of medicine.

[5]  M. Packer.  Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA , 2016, European journal of heart failure.

[6]  Akshay S. Desai,et al.  Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.

[7]  M. Packer.  Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. , 2016, JACC. Heart failure.

[8]  M. Petzold,et al.  Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians? , 2015, International journal of cardiology.

[9]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[10]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[11]  G. Fonarow,et al.  Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. , 2012, Congestive heart failure.

[12]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[13]  M. Komajda,et al.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey , 2007, European journal of heart failure.

[14]  G. Fonarow,et al.  Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). , 2007, American heart journal.

[15]  H. White,et al.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. , 2005, Journal of the American College of Cardiology.

[16]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[17]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[18]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[19]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[20]  Remme Wj.  Effect of ACE inhibition on neurohormones , 1998 .

[21]  G. Blackwell,et al.  Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction. , 1998, American heart journal.

[22]  W. Remme.  Effect of ACE inhibition on neurohormones. , 1998, European heart journal.

[23]  Early treatment with low-dose enalapril after acute myocardial infarction: An equilibrium radionuclide angiographic study , 1997, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[24]  E. McVeigh,et al.  Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. , 1995, The American journal of cardiology.

[25]  K. Swedberg,et al.  Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. , 1993, European heart journal.

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[28]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[29]  J. Whalen,et al.  Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects. , 1986, Journal of clinical hypertension.